Intellia Therapeutics Q3 net loss widens 26% to $127.49 million
Bitget2026/11/05 13:10- Intellia Therapeutics’ third-quarter 2026 net loss widened 26% year over year to $127.49 million.
- Collaboration revenue fell 48% to $7.16 million, primarily due to lower revenue from Regeneron.
- Cash, cash equivalents and marketable securities totaled $614.8 million at September 30, with existing resources expected to fund operations into at least 2028.
- Lonvo-z faces a March 10, 2027 FDA decision, with commercial launch planned for the first quarter of 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race
Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.
Bernstein Downgrades Nvidia Rating and Target Price
Google (GOOGL.US) DeepMind launches AlphaGenome 2: Capable of decoding DNA cells with nearly double the mutation identification capacity
Google DeepMind has released its AI model AlphaGenome 2, which is trained on maps of over 100 millions of cells and has nearly double the ability of its predecessor in identifying gene expression variations.
The White House did not intervene in the decision-making of Nvidia's board of directors.
Crypto prices
More
